|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
606.85
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | -2,790.90 | -867.48 | 656.46 | -638.12 | -191.11 | Adjustment | 2,032.98 | 722.01 | 496.84 | -61.66 | -70.83 | Changes In working Capital | -414.46 | -1,478.22 | -1,476.31 | 254.90 | -2,179.08 | Cash Flow after changes in Working Capital | -1,172.38 | -1,623.68 | -323.01 | -444.88 | -2,441.02 | Cash Flow from Operating Activities | -1,173.30 | -1,583.10 | -326.12 | -418.42 | -2,513.02 | Cash Flow from Investing Activities | 2,024.97 | 1,063.12 | -803.87 | -355.89 | -3,226.27 | Cash Flow from Financing Activities | -617.59 | 958.05 | -450.74 | -210.15 | -448.88 | Net Cash Inflow / Outflow | 234.08 | 438.07 | -1,580.72 | -984.47 | -6,188.17 | Opening Cash & Cash Equivalents | 941.27 | 525.99 | 2,030.79 | 1,886.58 | 6,603.09 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 381.33 | -22.78 | 75.92 | 1,128.67 | 1,471.66 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 0 | 0 | 0 | 0 | 0 | Closing Cash & Cash Equivalent | 1,556.68 | 941.27 | 525.99 | 2,030.79 | 1,886.58 |
|
|
|
|
|
|